LONDON & MUNICH & ZURICH--(BUSINESS WIRE)--May 18, 2026--
The Korean Ministry of Science and ICT (MSIT) will host the 2026 InnoCORE Global Postdoctoral Job Fair in June with upcoming programs in London, Munich, and Zurich. This follows the successful launch of the initiative in New York, Boston, and Silicon Valley in May 2026.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260518933593/en/
Organized by the MSIT together with KAIST, GIST, DGIST, and UNIST, the job fair will connect outstanding global postdoctoral researchers with leading Korean industries and research institutions.
The InnoCORE Postdoctoral Fellowship Program, launched in 2025, is a government-backed initiative to recruit outstanding early-career researchers from around the world in AI-convergent science and technology (AI+S&T). Following a strong reception in 2025—with over 100 postdoctoral researchers interviewed across three U.S. cities—the program is being significantly expanded in 2026, scaling up from an initial cohort of 400 to approximately 1,000 postdoctoral researchers. This year’s job fair series aims to further strengthen Korea’s global talent pipeline and deepen partnerships with leading academic and research institutions worldwide.
Building on 2025: Key Milestones
Since its launch in June 2025, the InnoCORE program has made significant strides in establishing Korea as a competitive destination for global research talent. Through overseas job fairs and recruitment campaigns led by the four institutes, 400 postdoctoral researchers were selected in the program’s inaugural year. Each fellow receives an annual base salary of KRW 90 million (approx. USD 62,000) plus KRW 60 million in dedicated research funding - roughly double the average compensation for postdoctoral researchers in Korea—reflecting the government’s commitment to attracting top-tier talent.
Looking ahead, the Korean government is significantly expanding the InnoCORE program in 2026. The scope of recruitment has broadened from AI and AI-convergent fields to all National Strategic Technology domains—including semiconductors & displays, next-generation batteries, advanced mobility, nuclear energy, advanced bio, space & aerospace, hydrogen, cybersecurity, AI, next-generation communications, advanced robotics & manufacturing, and quantum technology. The program is also being extended beyond the four institutes to include government-funded research institutions (GRIs) and universities.
2026 InnoCORE Global Job Fairs
The 2026 InnoCORE Global Postdoctoral Job Fair will continue in June in London, Munich, and Zurich. Each event will feature InnoCORE program briefings, research cluster presentations, and on-site interviews directly with Korean research group leaders.
Program Details
Backed by a five-year government investment of approximately USD 465 million, the InnoCORE fellowship offers an annual base salary of USD 62,000, with additional compensation available through research and industry partnerships. Fellows receive full access to Korea’s cutting-edge research infrastructure—including supercomputing systems, semiconductor cleanrooms, and biomedical research facilities—and benefit from a multi-mentor system connecting them with leading experts from both academia and industry, domestically and internationally.
Research & Recruitment Areas
InnoCORE will recruit 25 postdoctoral researchers per research group across 16 interdisciplinary research clusters (400 total), spanning four of Korea’s premier science and technology institutes.
How to Apply
Applicants must hold a PhD in a STEM-related field or must have successfully obtained their PhD by the confirmed appointment date. Further information on eligibility, research groups, and the application process is available at the official InnoCORE website: www.innocore-jobfair.com
An official timeline and guide for InnoCORE (Image: 2026 InnoCORE Global Postdoctoral Job Fair)
SANTA CLARA, Calif.--(BUSINESS WIRE)--May 18, 2026--
VahatiCor, Inc., a medtech company developing interventional therapies for Coronary Microvascular Dysfunction (CMD), announced today the appointment of Harry D. Rowland, Ph.D., as Chief Executive Officer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260517830314/en/
Rowland previously served as Chief Executive Officer and President of Endotronix, where he led the development and commercialization of the Cordella™ Pulmonary Artery Sensor and Heart Failure System. Under his leadership, Endotronix raised over $150 million and grew to more than 150 employees. He also oversaw the PROACTIVE-HF pivotal trial from execution through FDA premarket approval and commercial launch. Following its acquisition by Edwards Lifesciences in 2024, Rowland stayed on to support key CMS national coverage and CE Mark milestones.
"Harry has led a medical company through this arc before. He took Endotronix from clinical concept to FDA approval and subsequent acquisition by Edwards Lifesciences, building both the team and the supporting evidence base," said Marwan Berrada-Sounni, Co-Founder of VahatiCor. "As VahatiCor advances A-FLUX and continues to generate evidence for patients with Coronary Microvascular Dysfunction, we are confident that Harry is the right leader to bring this therapy forward."
VahatiCor is enrolling patients in SERRA-I, its early feasibility study of the A-FLUX Reducer System ®, while preparing for SERRA-II and advancing engineering, clinical, regulatory, and commercial initiatives. Rowland's experience guiding a cardiovascular medical technology company from clinical development through regulatory approval and commercialization will support VahatiCor's next phase of growth.
“I was immediately drawn to VahatiCor as a promising alternative treatment option for patients suffering from persistent chest pain. The A-FLUX hourglass-shaped implant, placed in the coronary sinus, is designed to increase blood flow to the microvasculature, reducing this pain and improving overall quality of life,” said Harry Rowland, CEO of VahatiCor. “I’m excited to join the talented VahatiCor team and partner with physician collaborators to grow the evidence to support clinical use and help patients in need.”
Coronary Microvascular Dysfunction (CMD) affects millions of patients who experience persistent angina (chest pain) and related symptoms without blockages in the large coronary arteries. VahatiCor is developing the A-FLUX Reducer System ®, a catheter-based intervention for patients with ongoing CMD symptoms despite medical therapy. The A-FLUX Reducer System® is investigational and has not received U.S. Food and Drug Administration approval for commercial use.
“Harry is the right leader for VahatiCor at this pivotal stage, when breakthrough technology requires disciplined execution,” said Brian R. Smith, Managing Director at S3 Ventures. “A-FLUX® represents a substantial opportunity to reach a large, underserved patient population, and Harry brings the proven ability to build the team, clinical evidence, and operational foundation needed to move that opportunity forward. His leadership brings to VahatiCor the operating strength and focus required for its next phase of growth.”
VahatiCor will participate in EuroPCR 2026 in Paris, France, from May 19 to 22. The company will host a scientific symposium, “Early Evidence from a Next-Generation Coronary Sinus Reducer for the Treatment of Coronary Microvascular Dysfunction,” on Wednesday, May 20, from 12:30 to 13:15 CEST in Room 241 at the Palais des Congrès. The symposium will feature continuous thermodilution, coronary sinus reducer therapy for microvascular dysfunction, and early clinical evidence from VahatiCor’s SERRA-I study.
About VahatiCor
VahatiCor, Inc. develops innovative medical technology solutions for patients with Coronary Microvascular Dysfunction (CMD), a debilitating condition affecting millions of people who experience chest pain despite having no blockages in their major coronary arteries. The A-FLUX Reducer System® introduces a new therapeutic pathway for patients affected by coronary microvascular dysfunction (CMD), a condition that can cause chest pressure, heaviness, and discomfort. With this advancement, VahatiCor is helping expand access to care for individuals who have long faced limited treatment options.
VahatiCor CEO, Harry D. Rowland, Ph.D.
